You are here: Industry Insights > Ajovy

News List

NICE publishes final guidance backing Teva's Ajovy for migraine pharmatimes
June 05, 2020
The National Institute for Health and Care Excellence (NICE) has now published final guidelines endorsing the NHS use of Teva’s Ajovy (fremanezumab) to prevent migraine.
Ajovy bags NICE approval pharmatimes
March 13, 2020
The National Institute for Health and Care Excellence (NICE) has recommended Teva’s Ajovy for the prophylaxis of migraine in adults with chronic migraine who have not responded to at least three prior preventive treatments.
Teva abandons Ajovy trial for cluster headaches pharmatimes
April 24, 2019
Teva has announced an update on its Ajovy (fremanezumab) clinical development for use in episodic cluster headache, after a Phase III study found that the primary endpoint for weekly average number of cluster headache attacks during the four-week treatmen
Teva scraps development of CGRP inhibitor Ajovy in cluster headaches firstwordpharma
April 24, 2019
Teva said Tuesday that it will end development of Ajovy (fremanezumab) in cluster headaches after a pre-specified futility analysis of a Phase III study in episodic cluster headache revealed that the trial’s primary endpoint is unlikely to be met.
European approval for Teva’s migraine drug Ajovy pharmatimes
April 02, 2019
Teva has received European Commission approval for its migraine drug, Ajovy (fremanezumab). The drug is a pre-filled syringe for the prophylaxis of migraine in adults who have at least four migraine days per month.
Teva shares soar after migraine treatment Ajovy approval pharmafile
September 20, 2018
Shares in the Israeli pharma firm Teva soared on Sunday after the announcement that the US Food and Drug Administration (FDA)...
FDA Approves Ajovy americanpharmaceuticalreview
September 18, 2018
The US Food and Drug Administration (FDA) has approved Ajovy (fremanezumab-vfrm) for the preventive treatment of migraine in adults...